...
首页> 外文期刊>OncoTargets and therapy >Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: a case report
【24h】

Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: a case report

机译:Lenvatinib联合nivolumab注射再加右肝切除术是治疗大面积肝细胞癌的可行方法:一例报告

获取原文
           

摘要

Hepatocellular carcinoma (HCC) is a highly aggressive malignant tumor. The survival of advanced HCC is very poor. In this case study, we describe the treatment of a 69-year-old woman diagnosed with massive hepatocellular carcinoma, the use of lenvatinib in combination with nivolumab injection in the preoperative adjuvant treatment of advanced massive hepatocellular carcinoma, and the final taking extended right hepatectomy. Molecular targeted drugs and immunotherapy controlled patient’s condition to create time and conditions for surgery. After surgery, AFP was greatly reduced, no recurrence of the residual liver and no metastasis in the distance. This treatment is the gospel of patients with advanced liver cancer.
机译:肝细胞癌(HCC)是一种高度侵袭性的恶性肿瘤。晚期肝癌的生存非常差。在本案例研究中,我们描述了对一名诊断为患有大面积肝细胞癌的69岁妇女的治疗,lenvatinib联合nivolumab注射液在晚期大块肝细胞癌的术前辅助治疗中的使用以及最终采取的扩大右肝切除术。分子靶向药物和免疫疗法控制了患者的病情,为手术创造了时间和条件。手术后,AFP大大减少,残留肝无复发,远处无转移。这种治疗是晚期肝癌患者的福音。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号